Sponsored Links
| Novagali Pharma Announces FDA Clearance Of IND For Phase III Of Catioprost(R), Its Cationic Emulsion Of Latanoprost In Patients With Glaucoma |
 |
 |
 |
| Medical News - Eye Health | |||
|
Novagali Pharma, a French pharmaceutical ophthalmic company, announces that the Company's Investigational New Drug Application (IND) to conduct a Phase III clinical trial of Catioprost(R) (Nova21027), for the treatment of glaucoma has been granted by the U.S. Food and Drug Administration (FDA). Read more: Eye Health / Blindness News From Medical News Today
|